Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 14, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
ConclusionsENZA treatment may be related to more favorable oncological outcomes than ABI treatment in the studied Polish population of patients. A 50% decline in PSA is an indicator of longer TTF and OS. Due to the non-randomized and retrospective nature of the analysis, the current results require prospective validation. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - April 3, 2023 Category: Cancer & Oncology Source Type: research
Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study
ConclusionBoth test and reference formulations of abiraterone acetate tablets were bioequivalent in healthy Chinese subjects under fasting conditions.Trial registrationClinicalTrials.gov identifier NCT04863105, registered 26 April 2021 —retrospectively registered (https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000ARAA&selectaction=Edit&uid=U00050YQ&ts=2&cx=-vbtjri (Source: Drugs in R&D)
Source: Drugs in R&D - April 3, 2023 Category: Drugs & Pharmacology Source Type: research
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
Oncologist. 2023 Mar 30:oyad008. doi: 10.1093/oncolo/oyad008. Online ahead of print.ABSTRACTNiraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling t...
Source: The Oncologist - March 30, 2023 Category: Cancer & Oncology Authors: Kim N Chi Neil Fleshner Vincenzo Emanuele Chiuri Siska Van Bruwaene Jason Hafron Douglas G McNeel Peter De Porre Raymond Scott Maul Mahesh Daksh Xiaogang Zhong Gary E Mason Ronald F Tutrone Source Type: research
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
CONCLUSION: The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.PMID:36996380 | DOI:10.1200/JCO.22.02394 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 30, 2023 Category: Cancer & Oncology Authors: Michael J Morris Glenn Heller David W Hillman Olivia Bobek Charles Ryan Emmanuel S Antonarakis Alan H Bryce Olwen Hahn Himisha Beltran Andrew J Armstrong Lawrence Schwartz Lionel D Lewis Jan H Beumer Brooke Langevin Eric C McGary Paul T Mehan Amir Goldkor Source Type: research
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
Oncologist. 2023 Mar 30:oyad008. doi: 10.1093/oncolo/oyad008. Online ahead of print.ABSTRACTNiraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling t...
Source: The Oncologist - March 30, 2023 Category: Cancer & Oncology Authors: Kim N Chi Neil Fleshner Vincenzo Emanuele Chiuri Siska Van Bruwaene Jason Hafron Douglas G McNeel Peter De Porre Raymond Scott Maul Mahesh Daksh Xiaogang Zhong Gary E Mason Ronald F Tutrone Source Type: research
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP.PMID:36952634 | DOI:10.1200/JCO.22.01649 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 23, 2023 Category: Cancer & Oncology Authors: Kim N Chi Dana Rathkopf Matthew R Smith Eleni Efstathiou Gerhardt Attard David Olmos Ji Youl Lee Eric J Small Andrea J Pereira de Santana Gomes Guilhem Roubaud Marniza Saad Bogdan Zurawski Valerii Sakalo Gary E Mason Peter Francis George Wang Daphne Wu Br Source Type: research
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP.PMID:36952634 | DOI:10.1200/JCO.22.01649 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 23, 2023 Category: Cancer & Oncology Authors: Kim N Chi Dana Rathkopf Matthew R Smith Eleni Efstathiou Gerhardt Attard David Olmos Ji Youl Lee Eric J Small Andrea J Pereira de Santana Gomes Guilhem Roubaud Marniza Saad Bogdan Zurawski Valerii Sakalo Gary E Mason Peter Francis George Wang Daphne Wu Br Source Type: research
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. ... (Source: BMC Cancer)
Source: BMC Cancer - March 7, 2023 Category: Cancer & Oncology Authors: Takashi Kawahara, Yusuke Saigusa, Shuko Yoneyama, Masashi Kato, Ippei Kojima, Hiroshi Yamada, Osamu Kamihira, Kenichi Tabata, Hideyasu Tsumura, Masatsugu Iwamura, Kazuhide Makiyama, Hiroji Uemura and Yasuhide Miyoshi Tags: Research Source Type: research
Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data
CONCLUSIONS: Our study sought to quantify risk of HHF, AMI and ischemic stroke among CRPC patients initiating AAP relative to ENZ within a national administrative claims database. Increased risk for HHF among AAP compared to ENZ users was observed. The difference in myocardial infarction did not attain statistical significance after controlling for residual bias, and no differences were noted in ischemic stroke between the two treatments. These findings confirm labeled warnings and precautions for AAP for HHF and contribute to the comparative real-world evidence on AAP relative to ENZ.PMID:36879362 | DOI:10.1002/pros.24510...
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Mitchell M Conover James Weaver Bo Fan Gerhard Leitz Ute Richarz Qing Li Dina Gifkins Source Type: research
225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
ConclusionsGiven these favorable results, randomized prospective multicenter trials assessing the clinical value of225Ac-PSMA-617 as a therapeutic agent for mHSPC administered either as monotherapy or administered concomitant with ADT are of interest. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - March 3, 2023 Category: Nuclear Medicine Source Type: research
